ALK and non-small cell lung carcinoma: These authors subsequently reported that ALK and KRAS mutations are associated with acquired resistance to crizotinib in ALK-positive NSCLC, suggesting that an ALK mutation detected in plasma can be a useful marker for response monitoring [51].